We signed one contract with a very important US partner for an additional 50 iBar systems which is our largest single order to date. These milestones highlight the escalation of our iBar land-and-expand strategy.
Record Q3 revenue at $2.9 million: up 66% year-over-year & 51% sequentially
Record net income at $0.9 million: up 200% year-over-year & 88% sequentially
Swiss drugmaker Novartis will invest up to an extra $15 million in Gamida Cell,
an Israeli developer of stem cell therapies, Gamida said on Sunday.
Supercom (NASDAQ:SPCB) will be announcing its Q215 earnings results on Wednesday, September 16th. Analysts expect the company to announce earnings of $0.28 per share and revenue of $9.86 million for the quarter.
The current $90 million value Mr. Market gives to ALL of RDHL's 9 late stage, promising programs is perhaps the most severe undervaluation with the best risk/reward in the whole biotech space. The situation won't last. To my best ability judging by value, timing, finances, science, insider ownership, the company's risk diversification and coming catalysts, RDHL is a BUY.
The most bullish analyst according to Zack’s Research has a one-year price target of $7.5 on shares of Top Image Systems, Ltd. (NASDAQ:TISA). When taking into account all of the research brokage firms polled by Zacks, the consensus price target sits at $5.666. This is based on the 3 providing one-year targets on the shares. On the contrary, the most bearish, or conservative analyst has a one year target of $4.5.